Martingale Asset Management L P Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Martingale Asset Management L P cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 21,711 shares of the biopharmaceutical company’s stock after selling 4,472 shares during the quarter. Martingale Asset Management L P’s holdings in Regeneron Pharmaceuticals were worth $22,823,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in REGN. Quent Capital LLC grew its stake in shares of Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares during the period. Cetera Investment Advisers raised its stake in shares of Regeneron Pharmaceuticals by 156.8% in the 1st quarter. Cetera Investment Advisers now owns 9,753 shares of the biopharmaceutical company’s stock valued at $9,387,000 after purchasing an additional 5,955 shares in the last quarter. Cetera Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 114.1% in the 1st quarter. Cetera Advisors LLC now owns 5,218 shares of the biopharmaceutical company’s stock valued at $5,022,000 after purchasing an additional 2,781 shares in the last quarter. Railway Pension Investments Ltd raised its stake in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Railway Pension Investments Ltd now owns 28,100 shares of the biopharmaceutical company’s stock valued at $27,046,000 after purchasing an additional 400 shares in the last quarter. Finally, Hamilton Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 72.0% in the 1st quarter. Hamilton Wealth LLC now owns 461 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 193 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Oppenheimer dropped their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Finally, Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Stock Up 0.2 %

Regeneron Pharmaceuticals stock opened at $754.87 on Friday. The company has a market capitalization of $82.95 billion, a P/E ratio of 18.68, a P/E/G ratio of 2.91 and a beta of 0.15. The firm’s fifty day simple moving average is $913.54 and its 200-day simple moving average is $1,020.69. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.